Assembly Biosciences (ASMB) Total Liabilities (2010 - 2026)

Assembly Biosciences' Total Liabilities history runs 17 years deep, the most recent figure standing at $36.9 million for Q1 2026.

• In Q1 2026, Total Liabilities fell 48.67% year-over-year to $36.9 million; the TTM figure through Mar 2026 stood at $36.9 million (down 48.67% YoY), while the FY2025 annual figure was $50.8 million, down 40.75% from the prior year.
• Total Liabilities for Q1 2026 stood at $36.9 million, down from $50.8 million in the prior quarter.
• The five-year high for Total Liabilities was $95.7 million in Q4 2023, with the low at $9.9 million in Q3 2023.
• The 5-year median for Total Liabilities is $50.8 million (2025), against an average of $47.7 million.
• The sharpest annual moves came in 2022 and 2024: Total Liabilities plunged 49.65% in 2022, then surged 648.96% in 2024.
• Assembly Biosciences' Total Liabilities stood at $19.1 million in 2022, then soared by 400.4% to $95.7 million in 2023, then decreased by 10.36% to $85.8 million in 2024, then sank by 40.75% to $50.8 million in 2025, then retreated by 27.42% to $36.9 million in 2026.
• Business Quant data shows ASMB's Total Liabilities at $36.9 million in Q1 2026, $50.8 million in Q4 2025, and $57.3 million in Q3 2025.